
Regeneron Pharmaceuticals, Inc.
REGNHealthcare|Biotechnology|US
$904.35
+1.45 (+0.16%)
DCF Value
$2028.80
Tangible Book / Share
$316.45
Graham Number
$592.50
Cash / Share
$91.46
Clinical Trials (511)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06665971 Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE) | Eosinophilic Esophagitis (EoE) | P4 | Recruiting | 30 | Open-label | Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT] |
| NCT07142343 A Study to Test the Safety of Pozelimab in Pediatric Participants 1 to 5 Years of Age With a Rare Disease Called CHAPLE (Complement Hyperactivation, Angiopathic Thrombosis, Protein-losing Enteropathy) Disease | CHAPLE Disease | P4 | Recruiting | 5 | Open-label | Pozelimab |
| NCT05983068 A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis | Dermatitis Atopic | P4 | Active | 48 | Open-label | dupilumab |
| NCT06352073 Dupilumab for Eosinophilic Esophagitis With Severe Strictures | Eosinophilic Esophagitis, EoE | P4 | Active | 23 | Open-label | Dupilumab |
| NCT05042258 Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis | Atopic Dermatitis, Sleep Disturbance | P4 | Recruiting | 40 | Open-label | Dupilumab |
| NCT06662994 High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy | Diabetic Macular Edema (DME) | P4 | Recruiting | 15 | Open-label | Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321) |
| NCT03935971 The Effects of Dupilumab on Allergic Contact Dermatitis | Allergic Contact Dermatitis | P4 | Active | 17 | Open-label | Dupilumab |
| NCT07053423 A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease. | Chronic Obstructive Pulmonary Disease | P4 | Recruiting | 218 | RCT, Double-blind | Dupilumab, Placebo |
| NCT05097287 Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma | Asthma | P4 | Active | 1,339 | RCT, Double-blind | Dupilumab, Placebo |
| NCT07587658 This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization | Chronic Obstructive Pulmonary Disease (COPD) | P4 | Recruiting | 754 | RCT, Double-blind | dupilumab, Placebo |
| NCT04380038 Viral Infection in Asthma (VIA) Study | Asthma | P4 | Recruiting | 60 | RCT, Double-blind | Dupilumab Injectable Product |
| NCT05268107 Ethnic Differences in Mechanisms of Action of Dupilumab | Atopic Dermatitis | P4 | Recruiting | 30 | Open-label | Dupilumab |
| NCT07609940 Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) | Relapsed/Refractory Multiple Myeloma (RRMM) | P4 | Recruiting | 30 | Open-label | Linvoseltamab, Tocilizumab |
| NCT05352672 Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma | Melanoma | P3 | Active | 1,546 | RCT, Double-blind | Fianlimab, Cemiplimab, Pembrolizumab, Placebo |
| NCT06230224 A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma (B-NHL) | P3 | Active | 216 | RCT, Open-label | Odronextamab, Ifosfamide, Carboplatin, Etoposide, Rituximab, Dexamethasone, Cisplatin, Cytarabine, Gemcitabine |
| NCT05991388 A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma | B-cell Non Hodgkin Lymphoma | P2P3 | Recruiting | 210 | Open-label | Odronextamab, Loncastuximab tesirine, Rituximab, Ifosfamide, Carboplatin, Etoposide, Etoposide Phosphate, Dexamethasone, CAR T-cells (TBC) |
| NCT07424144 An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps | Chronic Rhinosinusitis With Nasal Polyps | P3 | Active | 59 | RCT, Double-blind | Itepekimab (SAR440340), Placebo |
| NCT05800015 A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer | Non-small Cell Lung Cancer | P2P3 | Active | 160 | RCT, Double-blind | fianlimab, cemiplimab, Pemetrexed, Paclitaxel, Carboplatin, Cisplatin, Placebo |
| NCT07318610 Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease | Peripheral Artery Disease (PAD) | P3 | Recruiting | 7,050 | RCT, Double-blind | REGN7508, REGN9933, Placebo, Rivaroxaban |
| NCT05785767 A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) | Advanced Non-Small Cell Lung Cancer | P2P3 | Active | 149 | RCT, Double-blind | fianlimab, cemiplimab, Placebo |
| NCT06091254 A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma | Follicular Lymphoma (FL) | P3 | Recruiting | 822 | RCT, Open-label | Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/prednisolone, Bendamustine |
| NCT06293053 A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis | Prurigo Nodularis | P3 | Recruiting | 18 | Open-label | Dupilumab |
| NCT05608291 A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery | Melanoma | P3 | Active | 1,564 | RCT, Double-blind | Fianlimab, Cemiplimab, Pembrolizumab, Placebo |
| NCT06149286 A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma | Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) | P3 | Recruiting | 580 | RCT, Open-label | Odronextamab, Lenalidomide, Rituximab |
| NCT06932562 A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant | Multiple Myeloma | P3 | Recruiting | 1,000 | RCT, Open-label | Linvoseltamab, Daratumumab, Lenalidomide, Dexamethasone |
| NCT06091865 A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma | Diffuse Large B-cell Lymphoma (DLBCL) | P3 | Recruiting | 904 | RCT, Open-label | Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/Prednisolone |
| NCT07220785 Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy | Generalized Lipodystrophy | P3 | Recruiting | 28 | RCT, Double-blind | Mibavademab, Placebo |
| NCT06128629 MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | P3 | Recruiting | 1,200 | RCT, Double-blind | NTLA-2001, Placebo |
| NCT06585410 Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma (CSCC) | P3 | Recruiting | 369 | RCT, Open-label | Cemiplimab |
| NCT06541704 A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy | Age-related Macular Degeneration (AMD), Geographic Atrophy (GA) | P3 | Recruiting | 975 | RCT, Double-blind | Pozelimab, Cemdisiran, Placebo |
| NCT07854782 Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD | P3 | Recruiting | 1,500 | RCT, Double-blind | ALN-CIDEB, Placebo |
| NCT07154745 A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently | Paroxysmal Nocturnal Hemoglobinuria | P3 | Recruiting | 35 | Open-label | Pozelimab, Cemdisiran |
| NCT06931717 A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy | Non-Small Cell Lung Cancer | P3 | Recruiting | 390 | RCT, Open-label | Cemiplimab |
| NCT07220772 A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults | Monogenic Obesity | P3 | Recruiting | 4 | Open-label | Mibavademab |
| NCT03480568 Alirocumab in Patients on a Stable Dialysis Regimen | Hemodialysis, Peritoneal Dialysis | P3 | Recruiting | 20 | Open-label | Alirocumab 150 MG/ML [Praluent] |
| NCT07697599 Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC) | Venous Thromboembolism (VTE) | P3 | Recruiting | 1,908 | RCT, Double-blind | REGN7508, REGN9933, Placebo |
| NCT03969004 Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma | P3 | Active | 415 | RCT, Double-blind | Cemiplimab, Placebo |
| NCT05730036 A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma | Relapsed Refractory Multiple Myeloma (RRMM) | P3 | Recruiting | 410 | RCT, Open-label | Linvoseltamab, Elotuzumab, Pomalidomide, Dexamethasone |
| NCT07430956 Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable | Atrial Fibrillation (AF) | P3 | Recruiting | 2,628 | RCT, Double-blind | REGN7508, REGN9933, Placebo |
| NCT07309614 A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma | Asthma Control | P3 | Recruiting | 150 | RCT, Double-blind | Dupilumab Prefilled Syringe, Placebo Injection |
| NCT06491914 A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) | Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema | P3 | Active | 1,126 | Open-label | Aflibercept 8 mg |
| NCT06834347 A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps | Chronic Rhinosinusitis With Nasal Polyps | P3 | Active | 231 | RCT, Double-blind | Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS) |
| NCT06834360 A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps | Chronic Rhinosinusitis With Nasal Polyps | P3 | Active | 216 | RCT, Double-blind | Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS) |
| NCT07493304 Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers | Venous Thromboembolism (VTE) | P3 | Recruiting | 1,600 | RCT, Open-label | REGN7508, Apixaban |
| NCT06672237 A Phase 3 Study of NTLA-2001 in ATTRv-PN | Neuromuscular Disease, Neuromuscular Diseases (NMD) | P3 | Active | 67 | RCT, Double-blind | nexiguran ziclumeran, Normal Saline as Placebo |
| NCT06246916 A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | Melanoma | P3 | Recruiting | 560 | RCT, Open-label | fianlimab, cemiplimab, relatlimab+nivolumab |
| NCT07675811 A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy | Allergic Conjunctivitis | P3 | Recruiting | 570 | RCT, Double-blind | REGN-2Cat, Freneslerbart, Mevonlerbart, Placebo |
| NCT07410117 REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis | Cancer-Associated Thrombosis (CAT) | P3 | Recruiting | 1,120 | RCT, Double-blind | REGN7508, Placebo |
| NCT07626411 Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation | Atrial Fibrillation (AF) | P3 | Recruiting | 15,364 | RCT, Double-blind | REGN7508, Apixaban, Placebo |
| NCT04050436 Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer | Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma | P2 | Active | 231 | RCT, Open-label | Cemiplimab, RP1 |
| NCT04291105 Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients | Melanoma, Head and Neck Squamous Cell Carcinoma | P2 | Active | 87 | Open-label | VV1, Cemiplimab |
| NCT05347771 Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents | Asthma | P2 | Active | 240 | RCT, Double-blind | Dupilumab, Placebo |
| NCT07058012 A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE) | Colo-rectal Cancer | P2 | Recruiting | 79 | Open-label | Cemiplimab, cemiplimab plus fianlimab, cemiplimab + REGN7075 |
| NCT06444880 Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies | SMARCB1-Deficient Malignancies, Epithelioid Sarcoma | P2 | Active | 15 | Open-label | Ubamatamab, Cemiplimab |
| NCT07431086 Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US | Overweight or Obesity | P2 | Active | 120 | RCT, Double-blind | Olatorepatide, Placebo |
| NCT06190951 A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma | Melanoma | P2 | Active | 151 | RCT, Double-blind | cemiplimab, Fixed Dose Combination (FDC) cemiplimab+fianlimab, Placebo |
| NCT07455851 A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma | Relapsed Refractory Multiple Myeloma (RRMM) | P1P2 | Recruiting | 150 | Open-label | Linvoseltamab, REGN17372+Linvoseltamab |
| NCT04626635 A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers | Advanced Solid Tumors | P1P2 | Active | 548 | Open-label | REGN7075, Cemiplimab, Platinum-based doublet chemotherapy, Bevacizumab, Trifluridine-tipiracil |
| NCT06449313 Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features | Non-small Cell Lung Cancer Stage III | P2 | Recruiting | 21 | Open-label | Cemiplimab-Rwlc |
| NCT05553834 PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung | Non-small Cell Lung Cancer (NSCLC) | P2 | Active | 60 | Open-label | — |
| NCT07187401 A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor | Paroxysmal Nocturnal Hemoglobinuria (PNH), Persistent Anemia | P1P2 | Recruiting | 24 | RCT, Double-blind | ALN-CFB, Placebo |
| NCT07746388 Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial | Nsclc, NSCLC Stage II | P2 | Recruiting | 30 | Open-label | Cemiplimab |
| NCT05828511 A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment | Multiple Myeloma | P1P2 | Active | 148 | Open-label | Linvoseltamab |
| NCT06918132 Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma, Stage IB Lung Cancer AJCC v8 | P2 | Recruiting | 60 | Open-label | Cemiplimab, Fianlimab |
| NCT07281768 Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer | Colorectal Cancer | P2 | Recruiting | 66 | RCT, Open-label | Oxaliplatin, Capecitabine, Cemiplimab, Fianlimab, REGN7075 |
| NCT06292780 A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis) | Relapsed/Refractory Systemic Light Chain Amyloidosis | P1P2 | Recruiting | 220 | Open-label | Linvoseltamab |
| NCT06981325 Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients | Basal Cell Carcinoma (BCC), First Line Treatment | P2 | Recruiting | 34 | Open-label | Cemiplimab |
| NCT07154290 A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer | P2 | Recruiting | 300 | RCT, Open-label | Ubamatamab, Marlotamig, Sarilumab |
| NCT06651593 Phase II Biomarker Study of BND-22 in Combination With Cemiplimab in Solid Tumors | Solid Tumors | P2 | Recruiting | 40 | Open-label | SAR444881, Cemiplimab |
| NCT06887088 Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases | Melanoma BRAF V600E/K Mutated, Melanoma and Brain Metastases | P2 | Recruiting | 33 | Open-label | Encorafenib + Binimetinib, cemiplimab+fianlimab |
| NCT05125016 A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer | Metastatic Castration-resistant Prostate Cancer | P1P2 | Recruiting | 228 | Open-label | REGN4336, REGN5678 |
| NCT07175428 Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation | Atrial Fibrillation (AF) | P2 | Recruiting | 1,200 | RCT, Single-blind | REGN7508, REGN9933, Apixaban |
| NCT06226610 Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic | Pruritis | P2 | Recruiting | 46 | RCT, Double-blind | Dupilumab |
| NCT07631637 Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Metabolic Dysfunction-Associated Steatohepatitis (MASH) | P2 | Recruiting | 150 | RCT, Double-blind | ALN-CIDEB, Placebo |
| NCT07675824 REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension | Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT) | P1P2 | Recruiting | 271 | RCT, Double-blind | REGN22530 |
| NCT07234058 Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma | Pleural Mesotheliomas | P2 | Recruiting | 126 | RCT, Open-label | Cemiplimab, Fianlimab, Pemetrexed (Alimta), Cisplatin, Carboplatin (AUC 5) |
| NCT06910124 Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse | Multiple Myeloma | P2 | Recruiting | 32 | Open-label | Linvoseltamab, Lenalidomide |
| NCT06865339 Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer | NSCLC, Locally Advanced | P2 | Recruiting | 76 | Open-label | Cemiplimab, Fianlimab, Platinum Doublet Chemotherapy (PDC) |
| NCT05519475 A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | P2 | Recruiting | 120 | RCT, Double-blind | ALN-HSD, Placebo |
| NCT03951831 REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer | Prostate Cancer Metastatic | P2 | Active | 26 | Open-label | REGN2810, Degarelix, Leuprolide Acetate, Docetaxel |
| NCT02991469 A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS) | Juvenile Idiopathic Arthritis | P2 | Recruiting | 51 | Open-label | Sarilumab SAR153191 (REGN88) |
| NCT07251413 Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma | Cutaneous Basal Cell Carcinoma | P1P2 | Recruiting | 18 | RCT, Open-label | cemiplimab, Topical imiquimod |
| NCT03888105 A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies | B-cell Non-Hodgkin Lymphoma (B-NHL) | P2 | Active | 515 | Open-label | Odronextamab |
| NCT03761108 Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | P1P2 | Recruiting | 387 | Open-label | Linvoseltamab |
| NCT06385262 TOP 2301: Neoadjuvant Chemo for NSCLC | Non Small Cell Lung Cancer | P2 | Recruiting | 63 | Open-label | Alirocumab, Cemiplimab, Chemotherapy |
| NCT05720325 Dupilumab Effects Against Aeroallergen Challenge | Asthma, Allergic | P2 | Active | 96 | RCT, Double-blind | Dupilumab |
| NCT05878288 Deep sequencIng in Cutaneous Squamous CEll caRciNomas | Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck | P2 | Active | 11 | Open-label | Cemiplimab |
| NCT07704580 Phase 1b/2 Study of IV Sarilumab in Adult With RA | Rheumatoid Arthritis | P1P2 | Recruiting | 140 | RCT, Open-label | Sarilumab, SAR153191 SC, Sarilumab, SAR153191 IV |
| NCT07223541 Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | P2 | Recruiting | 72 | RCT, Open-label | Cemiplimab 350 MG Intravenous Solution, Fianlimab 1600 MG Intravenous Solution |
| NCT06769698 A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Head and Neck Squamous Cell Carcinoma (HNSCC) | P2 | Recruiting | 120 | RCT, Double-blind | FDC fianlimab+cemiplimab, Cemiplimab, Placebo |
| NCT06669247 A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma | Relapsed/Refractory Multiple Myeloma | P1P2 | Recruiting | 186 | Open-label | Linvoseltamab, REGN7945+Linvoseltamab |
| NCT06787612 Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer | Ovarian Cancer, Fallopian Tube Cancer | P2 | Recruiting | 397 | RCT, Open-label | Ubamatamab, Bevacizumab, Cemiplimab, Fianlimab, PLD, Sarilumab, REGN10597 |
| NCT06421636 A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body | Non-Transfusion Dependent Beta-Thalassemia (NTDT) | P2 | Active | 19 | RCT, Double-blind | REGN7999, Placebo |
| NCT04989946 Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer | Prostate Cancer | P1P2 | Active | 57 | RCT, Open-label | Degarelix, pTVG-AR, Nivolumab, Cemiplimab, Fianlimab, FLT PET/CT |
| NCT05955508 A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma | Smoldering Multiple Myeloma (SMM) | P2 | Active | 40 | RCT, Open-label | Linvoseltamab |
| NCT07685808 Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes | Overweight or Obesity | P2 | Recruiting | 360 | RCT, Double-blind | Olatorepatide, Placebo |
| NCT07235917 A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea | Functional Hypothalamic Amenorrhea, FHA | P2 | Recruiting | 34 | RCT, Double-blind | Mibavademab |
| NCT05551793 Regeneron AA Multicenter (Dupilumab) | Alopecia Areata | P2 | Recruiting | 76 | RCT, Double-blind | Dupilumab, Placebo |
| NCT07527910 A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | P2 | Recruiting | 204 | RCT, Double-blind | ALN-PNP, Tirzepatide, Placebo |
| NCT06448026 Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity and HPV-negative Oropharyngeal Squamous Cell Carcinoma | Locally Recurrent Oral Cavity Squamous Cell Carcinoma | P2 | Recruiting | 17 | Open-label | Cemiplimab, Cetuximab |
| NCT06623656 Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC | Carcinoma, Non-Small-Cell Lung | P2 | Recruiting | 112 | RCT, Open-label | Cemiplimab, Platinum based chemotherapy |
| NCT06351592 First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS) | Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene | P1P2 | Recruiting | 54 | RCT, Open-label | ALN-SOD, Placebo (PB) |
| NCT07188896 A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC) | Advanced Renal Cell Carcinoma (aRCC), Metastatic Renal Cell Carcinoma ( mRCC) | P2 | Recruiting | 120 | RCT, Open-label | Fianlimab, Ipilimumab, Nivolumab, Cemiplimab |
| NCT06836609 A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH) | Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis | P1P2 | Active | 118 | RCT, Double-blind | ALN-CIDEB, Placebo |
| NCT05557591 A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1) | Advanced Non-Small Cell Lung Cancer | P2 | Active | 51 | RCT, Open-label | BNT116, Cemiplimab |
| NCT07271186 Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease | Diabetic Kidney Disease (DKD) | P2 | Recruiting | 195 | RCT, Double-blind | ALN-ANG3, Evinacumab, Placebo |
| NCT05648214 A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | P1P2 | Recruiting | 172 | RCT, Double-blind | ALN-PNP, Placebo (PB) |
| NCT05961709 The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer | Colon Cancer | P2 | Active | 50 | Open-label | Cemiplimab |
| NCT03564340 Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers | Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer | P1P2 | Recruiting | 890 | Open-label | Ubamatamab, Cemiplimab, Sarilumab, Tocilizumab |
| NCT06299098 A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation | Obesity | P2 | Active | 1,005 | RCT, Double-blind | Trevogrumab-Part A, Trevogrumab-Part B and Part C, Garetosmab, Semaglutide, Matching Placebo-Part A, Matching Placebo-Trevogrumab, Matching Placebo-Garetosmab |
| NCT06161441 A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery | Resectable Non-small Cell Lung Cancer | P2 | Active | 195 | RCT, Double-blind | Fianlimab, Cemiplimab, Pemetrexed, Paclitaxel, Carboplatin, Cisplatin, Placebo |
| NCT06855212 Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC | Head and Neck Squamous Cell Carcinoma | P2 | Active | 22 | Open-label | Cemiplimab, Cetuximab |
| NCT07214727 A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease | Alzheimer's Disease | P1 | Recruiting | 50 | RCT, Double-blind | ALN-5288, Placebo |
| NCT07753148 Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation | Clonal Cytopenia of Undetermined Significance (CCUS), Low-Risk Myelodysplastic Syndrome (LR-MDS) | P1 | Recruiting | 52 | Open-label | REGN17235 |
| NCT06902376 XL092 and Cemiplimab in BRAF WT Thyroid Cancer | Anaplastic Thyroid Cancer, Thyroid Cancer | P1 | Recruiting | 12 | Open-label | Cemiplimab, XL092 |
| NCT05685173 A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas | B-cell Non-Hodgkins Lymphoma (B-NHL) | P1 | Recruiting | 107 | Open-label | Odronextamab, REGN5837 |
| NCT07527923 First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis | Healthy Volunteer, Atopic Dermatitis | P1 | Recruiting | 160 | RCT, Double-blind | REGN20423 |
| NCT05105152 PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML | Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory | P1 | Recruiting | 18 | Open-label | SC-DARIC33 |
| NCT07230834 Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants | Geographic Atrophy (GA) | P1 | Recruiting | 54 | RCT, Double-blind | Pozelimab |
| NCT03233139 Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies | Advanced Malignancies | P1 | Active | 146 | Open-label | Cemiplimab, Ipilimumab, Platinum-doublet chemotherapy, Gemcitabine, Pemetrexed, Paclitaxel, Fianlimab |
| NCT04722523 A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer | Head and Neck Cancer, Head Cancer | P1 | Recruiting | 40 | Open-label | Cisplatin, Carboplatin, Docetaxel, Cetuximab, Cemiplimab, Paclitaxel |
| NCT07594093 Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity | Overweight or Obesity | P1 | Recruiting | 90 | RCT, Double-blind | REGN20934, Placebo |
| NCT07526116 A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy Adults | Healthy Volunteer | P1 | Recruiting | 88 | RCT, Double-blind | REGN22044, Placebo |
| NCT07543055 A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread | Prostate Cancer | P1 | Recruiting | 36 | Open-label | — |
| NCT06469281 A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers | Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma | P1 | Recruiting | 90 | Open-label | Cemiplimab, Bevacizumab |
| NCT05704634 A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer. | Lung Cancer | P1 | Active | 56 | RCT, Open-label | Cemiplimab, Kevzara (Sarilumab) |
| NCT06452771 A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults | Healthy Volunteers With Hyperlipidemia | P1 | Active | 59 | RCT, Double-blind | ALN-ANG3, Placebo (PB) |
| NCT07759167 Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis | End-Stage Kidney Disease (ESKD) | P1 | Recruiting | 36 | RCT, Double-blind | REGN9933, REGN7508, REGN9533, Heparin |
| NCT07118306 COPD Exacerbation Follow Up | COPD (Chronic Obstructive Pulmonary Disease) | Recruiting | 485 | — | — | |
| NCT07444203 Transformative Research in Diabetic Nephropathy 2.0 | Diabetic Nephropathies, Kidney Diseases | Recruiting | 200 | — | Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Renin-angiotensin-aldosterone system blockade, Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Mineralocorticoid Receptor Antagonists(MRAs) | |
| NCT02622581 Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients | Metastatic Non-small Cell Lung Cancer (NSCLC), Non-small Cell Lung Cancer Metastatic | Recruiting | 14,500 | — | — | |
| NCT05568459 A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy | Hemophilia B | Active | 11 | — | — | |
| NCT06479863 Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis | Sporadic Inclusion Body Myositis (sIBM), Idiopathic Inflammatory Myopathies | Early P1 | Recruiting | 10 | Open-label | — |
| NCT06192563 A Study to Observe How Pediatric Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions Respond to Dupilumab Treatment | Atopic Dermatitis | Recruiting | 230 | — | Dupilumab | |
| NCT06798298 A Safety and Efficacy Long-Term Follow-up Study of Adult Participants Treated With Gene Modified T Cells | Long Term Safety Following GM T Cell Therapy | Recruiting | 50 | — | — | |
| NCT00707694 The Longevity Genes in Founder Populations Project | Extreme Longevity | Recruiting | 2,000 | — | — | |
| NCT06773897 Rutgers University Study of the Genetics of Breast Cancer. | Breast Cancer Risk, Breast Cancer Prevention | Recruiting | 25,000 | — | — | |
| NCT04959448 Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP) | Chronic Rhinosinusitis With Nasal Polyposis | Active | 717 | — | DUPIXENT® | |
| NCT05246267 Dupilumab Treatment Effects in an Ethnically Diverse Population With Chronic Rhinosinusitis With Nasal Polyposis | Chronic Rhinosinusitis With Nasal Polyps | Active | 60 | — | Dupilumab | |
| NCT07064330 Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treated With Cemiplimab. | Cutaneous Squamous Cell Carcinoma (CSCC) | Recruiting | 30 | — | Cemiplimab | |
| NCT07606508 Follow-up of a French National Cohort of Patients With Cutaneous Squamous Cell Carcinoma Requiring Systemic Treatment. | Cutaneous Squamous Cell Carcinoma (CSCC) | Recruiting | 1,500 | — | Systemic treatment | |
| NCT06415175 Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain | Atopic Dermatitis | Active | 143 | — | Dupilumab | |
| NCT07217535 Rutgers University Study of the Genetics of Kidney Disease | Kidney Disease, Kidney Disease, Chronic | Recruiting | 50,000 | — | — | |
| NCT06695897 A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany | Eosinophilic Esophagitis | Recruiting | 150 | — | Dupilumab | |
| NCT06169527 A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving Dupilumab | Atopic Dermatitis | Active | 303 | — | Dupilumab | |
| NCT07223411 Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma | Locally Advanced Melanoma | Recruiting | 20 | — | Fianlimab + Cemiplimab, Relatlimab + Nivolumab | |
| NCT03992417 Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD) | Dermatitis Atopic | Active | 955 | — | Dupilumab SAR231893 (REGN668) | |
| NCT00381121 University of Michigan "Nephrology Research BioBank" | Chronic Kidney Disease | Recruiting | 420 | — | — | |
| NCT03428646 Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD) | Dermatitis, Atopic | Active | 858 | — | Dupilumab | |
| NCT03389893 Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis | Atopic Dermatitis (AD) | P4 | Terminated | 72 | RCT, Double-blind | Dupilumab, Placebo |
| NCT05049122 Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52) | Chronic Rhinosinusitis With Nasal Polyps | P4 | Completed | 25 | Open-label | Dupilumab SAR231893 |
| NCT02120950 Aflibercept in Polypoidal Choroidal Vasculopathy | Neovascular Macular Degeneration | P4 | Completed | 333 | RCT, Double-blind | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) |
| NCT01543568 Study for Recalcitrant Age Related Macular Degeneration | Age Related Macular Degeneration | P4 | Completed | 46 | Open-label | aflibercept 2.0 mg |
| NCT07187089 Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With Dupilumab | Severe Atopic Dermatitis (AD) | P4 | Withdrawn | — | Open-label | dupilumab |
| NCT04502862 A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma | Asthma | P4 | Completed | 202 | RCT, Double-blind | SAR231893, Placebo |
| NCT03468296 Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept | Neovascular Age-related Macular Degeneration | P4 | Unknown | 22 | RCT, Open-label | Intravitreal Aflibercept Injection 2mg |
| NCT01870427 NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions | Macular Edema With Central Retinal Vein Occlusions | P4 | Completed | 20 | Open-label | Aflibercept (2.0 mg) |
| NCT04998604 EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients | Chronic Rhinosinusitis With Nasal Polyps, Asthma | P4 | Completed | 360 | RCT, Double-blind | Dupilumab, Omalizumab, Placebo |
| NCT01670162 On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD) | Age Related Macular Degeneration, Pigment Epithelial Detachment | P4 | Unknown | 30 | Open-label | Aflibercept |
| NCT04718870 Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis | Dermatitis Atopic | P4 | Completed | 41 | Open-label | Dupilumab SAR231893 |
| NCT04823130 Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis | Dermatitis Atopic | P4 | Completed | 54 | Open-label | Dupilumab (SAR231893) |
| NCT05265234 Dupilmuab for Atopic Dermatitis Monitored With Noninvasive Imaging. | Eczema, Atopic Dermatitis | P4 | Unknown | 15 | Open-label | Dupilumab |
| NCT03542110 The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial | Saphenous Vein Graft Atherosclerosis | P4 | Terminated | 46 | RCT, Double-blind | Alirocumab 150 MG/ML subcutaneous injection, Matching Placebo subcutaneous injection |
| NCT04447417 Dupilumab Skin Barrier Function Study in Atopic Dermatitis | Atopic Dermatitis | P4 | Completed | 52 | Open-label | Dupilumab SAR231893 |
| NCT02299336 Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial | Diabetic Macular Edema | P4 | Completed | 60 | Open-label | Aflibercept |
| NCT03667014 The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients | Atopic Dermatitis, Atopic Dermatitis Eczema | P4 | Completed | 34 | Open-label | Dupilumab |
| NCT04988022 Dupilumab in the Treatment of Keloids | Keloid | P4 | Completed | 44 | RCT, Double-blind | Dupilumab, Placebo |
| NCT01617148 Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept | Exudative Macular Degeneration | P4 | Completed | 26 | Open-label | Aflibercept |
| NCT03022292 The IAI-OCTA Study; a Study of OCT-Angiography Analysis Efficacy | Wet Macular Degeneration | P4 | Completed | 26 | Open-label | Aflibercept Ophthalmic |
| NCT02689518 EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection | Macular Degeneration, Wet Macular Degeneration | P4 | Completed | 50 | Open-label | Intravitreal aflibercept injection |
| NCT05036733 Effects of Interleukin (IL)- 4R-alpha Inhibition on Respiratory Microbiome and Immunologic Correlates in Severe Asthma | Asthma | P4 | Completed | 15 | Open-label | Dupilumab |
| NCT02305238 Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration | Wet Macular Degeneration | P4 | Completed | 288 | RCT, Open-label | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) |
| NCT05590585 Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial | Moderate-to-Severe Atopic Dermatitis, Atopic Eczema | P4 | Completed | 124 | Open-label | dupilumab |
| NCT01857544 Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy | Retinal Vein Occlusion | P4 | Unknown | 10 | Open-label | Aflibercept |
| NCT02581891 Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye | Macular Degeneration | P4 | Completed | 287 | RCT, Open-label | Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321), Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321) |
| NCT06591598 A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration | Diabetic Macular Edema, Neovascular Age-related Macular Degeneration | P4 | Completed | 51 | Open-label | Aflibercept (BAY86-5321, Eylea) |
| NCT06012448 The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity Reaction | Dermal Hypersensitivity Reaction | P4 | Completed | 10 | Open-label | Dupilumab |
| NCT04520308 An Open-label, Single-arm Longitudinal Study With Dupilumab for Patients With Atopic Dermatitis | Atopic Dermatitis, AD | P4 | Unknown | 45 | Open-label | Dupilumab Only Product |
| NCT03694197 Long Term Safety Study of PRALUENT | Heterozygous Familial Hypercholesterolemia, Non-familial Hypercholesterolemia | P4 | Terminated | 1,389 | Open-label | Praluent |
| NCT03293030 Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis | Atopic Dermatitis, Atopic Dermatitis Eczema | P4 | Completed | 17 | Open-label | Dupilumab |
| NCT04400318 The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma | Asthma | P4 | Completed | 109 | RCT, Double-blind | Dupilumab, Placebo |
| NCT04708145 Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial | Diabetic Retinopathy | P4 | Completed | 41 | RCT, Open-label | Aflibercept Injection |
| NCT01627249 Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema | Diabetic Macular Edema | P3 | Completed | 660 | RCT, Single-blind | 2.0 mg intravitreal aflibercept, 1.25 mg intravitreal bevacizumab, 0.3 mg intravitreal ranibizumab |
| NCT00561470 Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen | Colorectal Neoplasms, Neoplasm Metastasis | P3 | Completed | 1,226 | RCT, Double-blind | Placebo, Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin), FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) |
| NCT02325791 Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants | Respiratory Syncytial Virus Infections | P3 | Completed | 1,177 | RCT, Double-blind | Suptavumab 30 mg/kg, Placebo Matched to Suptavumab, Suptavumab 30 mg/kg- 1 Dose, Suptavumab 30 mg/kg - 2 Doses |
| NCT01730040 Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I) | Hypercholesterolemia | P3 | Completed | 355 | RCT, Double-blind | Alirocumab, Atorvastatin, Ezetimibe, Rosuvastatin, Placebo |
| NCT04417894 A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT) | Moderate to Severe Atopic Hand and Foot Dermatitis | P3 | Completed | 133 | RCT, Double-blind | dupilumab, Placebo |
| NCT03285646 Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee | Chronic Low Back Pain, Osteoarthritis | P3 | Terminated | 63 | RCT, Double-blind | Fasinumab, Placebo |
| NCT02898454 Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps | Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP) | P3 | Completed | 448 | RCT, Double-blind | Dupilumab SAR231893 (REGN668), Placebo, Mometasone furoate nasal spray |
| NCT00829829 PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1 | Intercritical Gout | P3 | Completed | 241 | RCT, Double-blind | Rilonacept 80 mg, Rilonacept 160 mg |
| NCT07901725 Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain Amyloidosis | Newly Diagnosed Amyloidosis, Amyloidosis Stage I-IIIA | P3 | Not Yet Recruiting | 382 | RCT, Open-label | Linvoseltamab, Daratumumab, Bortezomib, Cyclophosphamide, Dexamethasone |
| NCT01709500 Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy) | Heterozygous Familial Hypercholesterolemia | P3 | Completed | 249 | RCT, Double-blind | LMT (atorvastatin, simvastatin, or rosuvastatin), alirocumab, Placebo |
| NCT04101721 Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity | Retinopathy of Prematurity | P3 | Completed | 127 | RCT, Open-label | aflibercept |
| NCT00327444 Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites | Ovarian Neoplasms, Ascites | P2P3 | Completed | 58 | RCT, Double-blind | aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Placebo, aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) |
| NCT03510715 An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia | Hypercholesterolemia | P3 | Completed | 18 | Open-label | Alirocumab SAR236553 (REGN727), Atorvastatin, Simvastatin, Fluvastatin, Pravastatin, Lovastatin, Rosuvastatin, Ezetimibe, Cholestyramine, Nicotinic acid, Fenofibrate, Omega-3 fatty acids |
| NCT02396316 Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients | Glaucoma, Neovascular | P3 | Completed | 54 | RCT, Double-blind | Aflibercept (Eylea, BAY 86-5321), Sham Injection |
| NCT03156621 Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH) | Homozygous Familial Hypercholesterolemia | P3 | Completed | 69 | RCT, Double-blind | Alirocumab, Placebo |
| NCT04004208 Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy | Retinopathy of Prematurity (ROP) | P3 | Completed | 113 | RCT, Open-label | Eylea (Aflibercept, BAY86-5321) |
| NCT03600818 Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica | Polymyalgia Rheumatica | P3 | Terminated | 118 | RCT, Double-blind | Sarilumab SAR153191 (REGN88), Sarilumab-matching placebo, Prednisone, Prednisone-matching placebo, Prednisone |
| NCT01926782 Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1) | Hypercholesterolemia | P3 | Completed | 803 | RCT, Double-blind | Placebo (for alirocumab), Alirocumab, Statin |
| NCT01521559 Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO) | Branch Retinal Vein Occlusion | P3 | Completed | 183 | RCT, Double-blind | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) |
| NCT03304379 Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip | Osteoarthritis, Knee, Osteoarthritis, Hip | P3 | Completed | 1,650 | RCT, Double-blind | Fasinumab, Matching placebo |
| NCT01670721 Colorectal Cancer Metastatic | Colorectal Cancer Metastatic | P3 | Completed | 175 | Open-label | AFLIBERCEPT, Irinotecan, Fluorouracil, Leucovorin |
| NCT02373202 A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA) | Rheumatoid Arthritis | P3 | Completed | 91 | RCT, Double-blind | Sarilumab, Sulfasalazine, Leflunomide, Bucillamine, Tacrolimus, Mizoribine |
| NCT01331681 Intravitreal Aflibercept Injection in Vision Impairment Due to DME | Diabetes Mellitus, Macular Edema | P3 | Completed | 406 | RCT, Double-blind | VEGF Trap-Eye (BAY86-5321), VEGF Trap-Eye (BAY86-5321) |
| NCT06602739 A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy | Allergic Conjunctivitis | P3 | Completed | 54 | RCT, Double-blind | REGN5713, REGN5715, Placebo |
| NCT02612454 Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD) | Atopic Dermatitis | P3 | Completed | 880 | Open-label | Dupilumab |
| NCT04701983 Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Pulmonary Disease | P3 | Completed | 1,127 | RCT, Double-blind | Itepekimab SAR440340, Placebo |
| NCT03600805 Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA | Giant Cell Arteritis | P3 | Terminated | 83 | RCT, Double-blind | Sarilumab SAR153191, Sarilumab matching placebo, Prednisone, Prednisone matching placebo |
| NCT03620747 Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up) | Asthma | P3 | Completed | 393 | Open-label | Dupilumab SAR231893 (REGN668) |
| NCT04183335 Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME) | Neurodermatitis | P3 | Completed | 151 | RCT, Double-blind | Dupilumab SAR231893, Placebo, Moisturizers, Low to medium potent topical corticosteroids, Topical calcineurin inhibitors |
| NCT04425629 Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19 | COVID-19 | P3 | Terminated | 10,078 | Open-label | casirivimab+imdevimab combination therapy |
| NCT03409744 Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia | Homozygous Familial Hypercholesterolemia | P3 | Completed | 116 | Open-label | evinacumab |
| NCT02326220 Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy | Heterozygous Familial Hypercholesterolemia | P3 | Completed | 62 | RCT, Double-blind | Placebo, Alirocumab |
| NCT05850520 A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) | Macular Edema Secondary to Retinal Vein Occlusion | P3 | Completed | 892 | RCT, Double-blind | Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham |
| NCT00519285 Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer | Prostatic Neoplasms, Neoplasm Metastasis | P3 | Completed | 1,224 | RCT, Double-blind | Aflibercept, Placebo (for aflibercept), Docetaxel, Prednisone or Prednisolone |
| NCT01764997 An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate | Rheumatoid Arthritis | P3 | Terminated | 776 | RCT, Double-blind | Sarilumab, Etanercept, Methotrexate, Placebo (for sarilumab), Placebo (for etanercept), Adalimumab |
| NCT01949311 Open-label Study of Dupilumab in Patients With Atopic Dermatitis | Atopic Dermatitis | P3 | Completed | 2,733 | Open-label | Dupilumab |
| NCT04452318 COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay | Healthy Participants | P3 | Completed | 3,303 | RCT, Double-blind | REGN10933 + REGN10987, Placebo |
| NCT04423718 Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye | Neovascular Age-Related Macular Degeneration | P3 | Completed | 1,011 | RCT, Double-blind | Aflibercept High Dose VEGF Trap-Eye (BAY86-5321), Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321) |
| NCT01909791 Treatment for CI-DME in Eyes With Very Good VA Study | Diabetic Macular Edema | P3 | Completed | 702 | RCT, Single-blind | Prompt aflibercept, Deferred aflibercept |
| NCT02634333 Anti-VEGF Treatment for Prevention of PDR/DME | Diabetic Retinopathy, Diabetic Macular Edema | P3 | Completed | 399 | RCT, Double-blind | Prompt aflibercept, Deferred aflibercept |
| NCT04315298 Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | COVID-19 | P2P3 | Completed | 1,912 | RCT, Double-blind | Sarilumab, Placebo |
| NCT01661270 A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy | Colorectal Cancer Metastatic | P3 | Completed | 332 | RCT, Double-blind | Aflibercept, Placebo |
| NCT03633617 Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE) | Eosinophilic Esophagitis | P3 | Completed | 321 | RCT, Double-blind | Dupilumab, Placebo |
| NCT03257267 Study of Cemiplimab in Adults With Cervical Cancer | Squamous Cell Carcinoma (SCC), Recurrent or Metastatic, Platinum-refractory Cervical Cancer | P3 | Completed | 608 | RCT, Open-label | Cemiplimab, Investigator Choice (IC) Chemotherapy |
| NCT03345914 Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD) | Dermatitis, Atopic | P3 | Completed | 367 | RCT, Double-blind | Dupilumab, Matching Placebo |
| NCT06208306 A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD | Chronic Obstructive Pulmonary Disease | P3 | Completed | 669 | RCT, Double-blind | Itepekimab (SAR440340), Placebo |
| NCT04015180 Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090 | Retinopathy of Prematurity (ROP) | P3 | Completed | 100 | Open-label | Eylea (Aflibercept, BAY86-5321) |
| NCT02948959 Evaluation of Dupilumab in Children With Uncontrolled Asthma | Asthma | P3 | Completed | 408 | RCT, Double-blind | Dupilumab, Placebo, Asthma Controller Therapies, Asthma Reliever Therapies |
| NCT00637377 Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) | Macular Degeneration | P3 | Completed | 1,240 | RCT, Double-blind | Ranibizumab, Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321), Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321), Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) |
| NCT02057250 To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis | RA | P3 | Completed | 217 | RCT, Open-label | Sarilumab, Methotrexate, Sulfasalazine, Leflunomide, Hydroxychloroquine |
| NCT01459796 Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares | Gout | P3 | Terminated | 220 | RCT, Double-blind | Rilonacept, Placebo, Allopurinol |
| NCT03930732 Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation | Chronic Obstructive Pulmonary Disease | P3 | Completed | 939 | RCT, Double-blind | Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo |
| NCT01709578 To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET) | Rheumatoid Arthritis | P3 | Completed | 546 | RCT, Double-blind | Sarilumab, placebo, hydroxychloroquine, methotrexate, sulfasalazine, leflunomide |
| NCT02585778 Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin) | Hypercholesterolaemia | P3 | Completed | 517 | RCT, Double-blind | Alirocumab, Placebo, Lipid-Modifying Therapy (LMT), Antihyperglycemic Drug |
| NCT03161093 A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip | Osteoarthritis, Knee, Osteoarthritis, Hip | P3 | Completed | 3,307 | RCT, Double-blind | Fasinumab, Naproxen, Fasinumab-matching placebo, Naproxen-matching placebo |
| NCT02289963 Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan | Hypercholesterolemia | P3 | Completed | 199 | RCT, Double-blind | Placebo (for Alirocumab), Alirocumab, Lipid-Modifying Therapy (LMT) |
| NCT06687967 A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1) | Lichen Simplex Chronicus | P3 | Completed | 142 | RCT, Double-blind | Dupilumab, Placebo |
| NCT01249664 VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV) | Myopia, Pathological | P3 | Completed | 122 | RCT, Double-blind | VEGF Trap-Eye (BAY86-5321) |
| NCT04456673 Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation | Chronic Obstructive Pulmonary Disease | P3 | Completed | 935 | RCT, Double-blind | Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo |
| NCT04206553 A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid | Bullous Pemphigoid | P2P3 | Completed | 106 | RCT, Double-blind | dupilumab, Matching Placebo, Oral corticosteroids (OCS) |
| NCT01730053 Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II) | Hypercholesterolemia | P3 | Completed | 305 | RCT, Double-blind | Alirocumab, Rosuvastatin, Ezetimibe, Placebo |
| NCT01644188 Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II) | Hypercholesterolemia | P3 | Completed | 720 | RCT, Double-blind | Alirocumab, Placebo (for alirocumab), Ezetimibe, Placebo (for ezetimibe), Lipid Modifying Therapy (LMT) |
| NCT01512966 Japanese Safety Study of VEGF Trap-Eye in DME (Diabetic Macular Edema) | Macular Edema | P3 | Completed | 73 | Open-label | VEGF Trap-Eye (BAY86-5321) |
| NCT07484230 A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Adult Japanese Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps | Chronic Rhinosinusitis With Nasal Polyps | P3 | Withdrawn | — | RCT, Double-blind | Itepekimab (SAR440340), Placebo |
| NCT01571284 Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen | Colorectal Cancer Metastatic | P3 | Completed | 781 | Open-label | AFLIBERCEPT AVE0005, FOLFIRI |
| NCT02293902 A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI) | Rheumatoid Arthritis | P3 | Completed | 243 | RCT, Double-blind | Sarilumab SAR153191 (REGN88), Methotrexate, Folic acid |
| NCT02277743 Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis | Dermatitis, Atopic | P3 | Completed | 671 | RCT, Double-blind | Dupilumab, Placebo (for Dupilumab) |
| NCT02121210 To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA) | Rheumatoid Arthritis | P3 | Completed | 132 | RCT, Open-label | sarilumab SAR153191 (REGN88) |
| NCT02755649 A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable | Atopic Dermatitis | P3 | Completed | 325 | RCT, Double-blind | Dupilumab, Matching Placebo |
| NCT04751487 Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Pulmonary Disease | P3 | Completed | 1,234 | RCT, Double-blind | Itepekimab SAR440340, Placebo |
| NCT03912259 Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | P3 | Completed | 165 | RCT, Double-blind | Dupilumab, Placebo, Emollient (moisturizer) |
| NCT03054428 Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis | Moderate-to-Severe Atopic Dermatitis, Dermatitis, Dermatitis Atopic | P3 | Completed | 251 | RCT, Double-blind | Dupilumab, Placebo |
| NCT04202679 Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2) | Neurodermatitis | P3 | Completed | 160 | RCT, Double-blind | Dupilumab SAR231893, Placebo, Moisturizers, Low to medium potent topical corticosteroids, Topical calcineurin inhibitors |
| NCT01012973 Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO) | Retinal Vein Occlusion | P3 | Completed | 177 | RCT, Double-blind | Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) |
| NCT01617655 Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH) | Hypercholesterolaemia | P3 | Completed | 107 | RCT, Double-blind | Alirocumab, Placebo (for alirocumab), Lipid Modifying Therapy (LMT) |
| NCT04684524 Dupilumab in Allergic Fungal Rhinosinusitis (AFRS) | Allergic Fungal Rhinosinusitis | P3 | Completed | 62 | RCT, Double-blind | Dupilumab SAR231893, Placebo |
| NCT04981717 A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat | Allergic Rhinitis Due to Cat Allergy | P3 | Terminated | 446 | RCT, Double-blind | REGN1908-1909, Matching Placebo |
| NCT03088540 Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) | Carcinoma,Non-Small-Cell Lung, Lung Carcinomas, Non-Small-Cell | P3 | Completed | 712 | RCT, Open-label | Pemetrexed, Paclitaxel, Gemcitabine, Cisplatin, Carboplatin, cemiplimab |
| NCT03515629 REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer | Non-small Cell Lung Cancer | P3 | Terminated | 5 | RCT, Open-label | REGN2810/ipi, REGN2810/chemo/ipi, Pembrolizumab |
| NCT07309432 Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy | Allergic Conjunctivitis | P3 | Terminated | 24 | RCT, Double-blind | REGN5713, REGN5715, Placebo |
| NCT02584504 Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin | Hypercholesterolemia | P3 | Completed | 163 | RCT, Double-blind | Alirocumab, Placebo, Atorvastatin, Non-statin Lipid-Modifying Therapy |
| NCT01709513 Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE) | Hypercholesterolemia | P3 | Completed | 314 | RCT, Double-blind | Atorvastatin, Ezetimibe, Alirocumab, Placebo |
| NCT06687980 A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2) | Lichen Simplex Chronicus | P3 | Completed | 138 | RCT, Double-blind | Dupilumab, Placebo |
| NCT03067844 Vascular Effects of Alirocumab in Acute MI-Patients | Coronary Vessel, Coronary Circulation | P3 | Completed | 294 | RCT, Double-blind | Alirocumab |
| NCT02395133 A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD) | Atopic Dermatitis | P3 | Completed | 422 | RCT, Double-blind | Dupilumab, Placebo |
| NCT02912468 A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps | Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP) | P3 | Completed | 276 | RCT, Double-blind | Dupilumab SAR231893 (REGN668), Placebo, Mometasone furoate 50 micrograms |
| NCT03782532 Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma | Asthma | P3 | Completed | 486 | RCT, Double-blind | Dupilumab SAR231893, Placebo, Asthma Controller Therapies (include prednisone/prednisolone), Asthma Reliever Therapies |
| NCT01146652 Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND) | Rheumatoid Arthritis | P3 | Completed | 2,023 | Open-label | SAR153191 (REGN88) |
| NCT03510884 An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia | Hypercholesterolaemia | P3 | Completed | 153 | RCT, Double-blind | Alirocumab SAR236553 (REGN727), Rosuvastatin, Atorvastatin, Simvastatin, Pravastatin, Lovastatin, Fluvastatin, Ezetimibe, Cholestyramine, Nicotinic acid, Fenofibrate, Omega-3 fatty acids, Placebo |
| NCT01363440 Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema | Diabetic Macular Edema | P3 | Completed | 466 | RCT, Double-blind | Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) |
| NCT03346434 Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL) | Dermatitis, Atopic | P2P3 | Completed | 202 | Open-label | Dupilumab, Matching placebo |
| NCT04327388 Sarilumab COVID-19 | Corona Virus Infection | P3 | Completed | 420 | RCT, Double-blind | Sarilumab SAR153191, Placebo |
| NCT07559513 A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP) | Fibrodysplasia Ossificans Progressiva, FOP | P3 | Not Yet Recruiting | 18 | Open-label | garetosmab |
| NCT07919899 Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) Coformulation | Dermatitis Atopic | P3 | Not Yet Recruiting | 150 | RCT, Open-label | Dupilumab coformulated with berahyaluronidase alfa, Dupilumab |
| NCT00509795 Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD) | Macular Degeneration | P3 | Completed | 1,217 | RCT, Double-blind | ranibizumab, aflibercept injection (VEGF Trap-Eye, BAY86-5321), aflibercept injection (VEGF Trap-Eye, BAY86-5321), aflibercept injection (VEGF Trap-Eye, BAY86-5321) |
| NCT03409614 Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer | Non-small Cell Lung Cancer | P3 | Completed | 789 | RCT, Double-blind | REGN2810, REGN2810/chemo/ipi, Placebo |
| NCT05989126 Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS) | Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD) | P3 | Completed | 35 | Open-label | aflibercept 8 mg PFS |
| NCT02476006 Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE) | Hypercholesterolemia | P3 | Completed | 998 | Open-label | ALIROCUMAB SAR236553 (REGN727), placebo (for injection training only), ezetimibe, atorvastatin, rosuvastatin, simvastatin |
| NCT03399786 Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia | Homozygous Familial Hypercholesterolemia | P3 | Completed | 65 | RCT, Double-blind | evinacumab, Placebo |
| NCT03682770 Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy) | Peanut Allergy | P2 | Completed | 148 | RCT, Double-blind | Dupilumab, Placebo matching dupilumab, AR101 |
| NCT03294083 A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma | Renal Cell Carcinoma | P1P2 | Completed | 95 | RCT, Open-label | Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab |
| NCT04502966 Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction | Allergic Rhinoconjunctivitis, Grass Pollen Allergy | P2 | Completed | 199 | RCT, Double-blind | Dupixent®, Grazax®, Dupixent® Placebo, Grazax® Placebo |
| NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | Solid Tumor, Adult, Advanced Solid Tumor | P1P2 | Completed | 98 | Open-label | SNS-101 (anti-VISTA), Cemiplimab |
| NCT01988246 Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery | Diabetic Retinopathy | P1P2 | Completed | 30 | RCT, Single-blind | Aflibercept, Sham |
| NCT02085005 Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancer | Colorectal Cancer Metastatic | P2 | Withdrawn | — | Open-label | Capecitabine, Aflibercept AVE0005, Oxaliplatin SR96669 |
| NCT03430063 A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer | Advanced Non-Small Cell Lung Carcinoma | P2 | Terminated | 28 | RCT, Open-label | SDREGN2810, SDREGN2810/ipi, HDREGN2810 |
| NCT06454630 A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants | Venous Thromboembolism | P2 | Completed | 179 | RCT, Open-label | REGN7508, Enoxaparin |
| NCT07863024 Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors | Advanced Solid Tumors | P1P2 | Not Yet Recruiting | 320 | RCT, Open-label | REGN13089-M404-M2980 |
| NCT04242173 Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC | Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck | P2 | Terminated | 3 | Open-label | Cemiplimab-Rwlc |
| NCT06122922 Xenon MRI in Stable Pulmonary Hypertension (Jupiter AUGEAN) | Pulmonary Artery Hypertension | P2 | Withdrawn | — | Open-label | Hyperpolarized Xe129 |
| NCT06848088 A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment | Melanoma | P2 | By Invite | 48 | Open-label | Fianlimab+cemiplimab |
| NCT03669718 A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC | Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive | P2 | Unknown | 194 | RCT, Double-blind | ISA101b, Cemiplimab |
| NCT03738423 Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis | Atopic Dermatitis | P2 | Terminated | 129 | RCT, Double-blind | REGN3500, REGN3500-Matching Placebo |
| NCT03787095 Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART | HIV Infections | P1P2 | Terminated | 5 | RCT, Double-blind | Cemiplimab, Placebo |
| NCT04373083 Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma | Hodgkin Lymphoma | P2 | Withdrawn | — | RCT, Open-label | Cemiplimab |
| NCT02379052 Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE) | Eosinophilic Esophagitis | P2 | Completed | 47 | RCT, Double-blind | Dupilumab, Placebo |
| NCT07887750 REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs) | Diffuse Large B-Cell Lymphoma (DLBCL) | P1P2 | Not Yet Recruiting | 36 | Open-label | REGN9220, Odronextamab |
| NCT04256759 Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus | Pruritus | P2 | Completed | 9 | Open-label | Dupilumab 300Mg Solution for Injection |
| NCT06237309 REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction | Heart Failure | P2 | Terminated | 89 | RCT, Double-blind | REGN5381, Placebo |
| NCT03949673 Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip | Osteoarthritis, Knee, Osteoarthritis, Hip | P2 | Terminated | 23 | Open-label | Fasinumab, Naproxen, Diclofenac, Celecoxib, Placebo |
| NCT02045030 Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer | Metastatic Colorectal Cancer | P2 | Terminated | 14 | Open-label | aflibercept + FOLFIRI |
| NCT04888507 Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy | Paroxysmal Nocturnal Hemoglobinuria | P2 | Completed | 6 | Open-label | Pozelimab, Cemdisiran |
| NCT06571708 Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT) | Bladder Cancer, Muscle-Invasive Bladder Carcinoma | P2 | Terminated | 1 | RCT, Open-label | Gemcitabine, Cisplatin, Cemiplimab, Fianlimab |
| NCT02573233 Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma | Asthma | P2 | Completed | 42 | RCT, Double-blind | Placebo, Dupilumab SAR231893/REGN668, fluticasone propionate and salmeterol, budesonide and formoterol, mometasone furoate and formoterol |
| NCT01061723 Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis | Ankylosing Spondylitis | P2 | Completed | 301 | RCT, Double-blind | Sarilumab, Placebo |
| NCT03956550 A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee | Osteoarthritis of the Knee, Pain | P2 | Terminated | 259 | RCT, Double-blind | REGN5069, Matching Placebo |
| NCT01859988 Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis | Atopic Dermatitis | P2 | Completed | 380 | RCT, Double-blind | Dupilumab, Placebo |
| NCT02713204 Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection | Neovascular Age-Related Macular Degeneration | P2 | Completed | 365 | RCT, Double-blind | REGN910-3, Intravitreal Aflibercept Injection (IAI) |
| NCT01920893 An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis | Nasal Polyps | P2 | Completed | 60 | RCT, Double-blind | Placebo (for dupilumab), Dupilumab, Mometasone furoate nasal spray |
| NCT05088460 A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD) | Familial Partial Lipodystrophy, Metabolic Abnormalities | P2 | Terminated | 20 | RCT, Double-blind | REGN4461, Matching Placebo |
| NCT02265952 Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH) | Homozygous Familial Hypercholesterolemia | P2 | Completed | 9 | Open-label | REGN1500 250 mg SC/15 mg/kg IV/450 mg SC |
| NCT07836101 Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events | Any Advanced Solid Tumors | P2 | Not Yet Recruiting | 41 | Open-label | Sarilumab, ICI Therapy |
| NCT04083534 First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM) | Relapsed Multiple Myeloma, Refractory Multiple Myeloma | P1P2 | Completed | 43 | Open-label | REGN5459 |
| NCT05202288 Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers | Ebola Virus Disease | P2 | Not Yet Recruiting | 132 | RCT, Open-label | Ervebo, Inmazeb |
| NCT00396591 AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites | Ovarian Neoplasms | P2 | Completed | 16 | Open-label | Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) |
| NCT04339062 Cemiplimab in AlloSCT/SOT Recipients With CSCC | Cutaneous Squamous Cell Carcinoma, Advanced Cancer | P1P2 | Completed | 12 | Open-label | Cemiplimab, Everolimus, Sirolimus, Prednisone |
| NCT04362501 Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) | Chronic Sinusitis | P2 | Completed | 33 | RCT, Double-blind | dupilumab, placebo |
| NCT07850921 REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants | Metastatic Castration-Resistant Prostate Cancer, mCRPC | P1P2 | Not Yet Recruiting | 192 | Open-label | REGN21353, Nezastomig, Sarilumab Prophylaxis (Contingency) |
| NCT07567469 A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma | High-Grade Glioma (HGG), Posterior Fossa-A Ependymoma | P1P2 | Not Yet Recruiting | 120 | RCT, Open-label | Cemiplimab, Cemiplimab+Fianlimab Fixed Dose Combination (FDC) |
| NCT04588948 A Pharmacokinetic stuDy of intRavitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Diabetic Macular Edema | Diabetic Macular Edema | P2 | Withdrawn | — | Open-label | Intravitreal Aflibercept |
| NCT01955629 Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient | Colorectal Cancer Metastatic | P1P2 | Terminated | 4 | Open-label | Aflibercept AVE0005, Oxaliplatin, Capecitabine |
| NCT01604824 A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene | Hypercholesterolemia | P2 | Completed | 23 | RCT, Double-blind | Alirocumab, Placebo |
| NCT01288469 Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia | Hypercholesterolemia | P2 | Completed | 92 | RCT, Double-blind | Alirocumab, Placebo (for alirocumab), Atorvastatin, Placebo (for atorvastatin) |
| NCT04296864 Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC) | Atopic Keratoconjunctivitis | P2 | Unknown | 42 | RCT, Double-blind | Dupilumab |
| NCT03678545 Dupilumab in Eosinophilic Gastritis | Eosinophilic Gastritis, Eosinophilic Gastroenteritis | P2 | Completed | 41 | RCT, Double-blind | Dupilumab (blinded), Placebo (blinded) |
| NCT02890992 An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia | Hypercholesterolaemia | P2 | Completed | 42 | Open-label | alirocumab SAR236553 (REGN727), statins, ezetimibe, cholestyramine, fenofibrate, omega-3 fatty acids, nicotinic acid |
| NCT07808138 RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer | Non Small Cell Lung Cancer, Immunotherapy | P2 | Not Yet Recruiting | 30 | Open-label | Cemiplimab 350 mg IV |
| NCT03886493 Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer | Prostate Cancer | P2 | Terminated | 7 | Open-label | Dupilumab |
| NCT04154943 Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma | P2 | Completed | 79 | Open-label | Cemiplimab |
| NCT07832370 A Trial of ALN-6457 in Adult Participants With Symptomatic Prion Disease (PrD) | Prion Disease | P1P2 | Not Yet Recruiting | 60 | Open-label | ALN-6457 |
| NCT00609544 Study of the Safety and Effectiveness of Rilonacept (IL-1 Trap) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia | Chronic Kidney Disease, Anemia | P2 | Withdrawn | — | RCT, Double-blind | Rilonacept |
| NCT07414992 A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer | Bladder Urothelial Carcinoma | P2 | Withdrawn | — | Open-label | Cemiplimab, Cemiplimab and Fianlimab |
| NCT04852978 COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers | Healthy, Chronic Stable Illness | P2 | Completed | 295 | RCT, Open-label | casirivimab+imdevimab, Moderna mRNA-1273 vaccine |
| NCT03793608 Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy | Peanut Allergy | P2 | Completed | 25 | Open-label | Dupilumab |
| NCT02171416 Cold Contact Urticaria Treatment With Rilonacept | Cold Contact Urticaria | P2 | Completed | 20 | RCT, Double-blind | Rilonacept, Placebo |
| NCT01538719 IL1-TRAP, Rilonacept, in Systemic Sclerosis | Scleroderma, Systemic Sclerosis | P1P2 | Completed | 24 | RCT, Double-blind | Rilonacept |
| NCT01266876 Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia | Hypercholesterolemia | P2 | Completed | 77 | RCT, Double-blind | Alirocumab, Placebo |
| NCT04159415 Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy | Generalized Lipodystrophy | P2 | Completed | 16 | RCT, Double-blind | Placebo, Low-Dose REGN4461, High-dose REGN4461 |
| NCT02712008 Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema | Diabetic Macular Edema | P2 | Completed | 302 | RCT, Double-blind | REGN910-3, Intravitreal Aflibercept Injection (IAI) |
| NCT04398524 A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC | Squamous Cell Carcinoma of the Oropharynx | P2 | Unknown | 65 | Open-label | ISA101b |
| NCT03558997 Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy | Allergic Rhinitis | P2 | Completed | 103 | RCT, Double-blind | Dupilumab, Timothy Grass SCIT, Placebo matching dupilumab, Placebo matching SCIT |
| NCT04148352 Dupilumab and Milk OIT for the Treatment of Cow's Milk Allergy | Allergies Food Milk | P2 | Terminated | 33 | RCT, Double-blind | Dupilumab |
| NCT03838731 Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge | Cat Allergy, Mild Asthma | P2 | Completed | 56 | RCT, Double-blind | REGN1908-1909, Placebo |
| NCT03387852 Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants | Asthma | P2 | Completed | 296 | RCT, Double-blind | SAR440340, Dupilumab, Fluticasone or Fluticasone/salmeterol combination, Placebo for SAR440340, Placebo for dupilumab |
| NCT03712904 Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma | Uveal Melanoma | P2 | Terminated | 3 | RCT, Open-label | Ziv-Aflibercept |
| NCT02776735 An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) | Juvenile Idiopathic Arthritis | P2 | Completed | 102 | Open-label | Sarilumab |
| NCT03085784 Intravitreal Aflibercept Injection for Radiation Retinopathy Trial | Radiation Retinopathy | P2 | Unknown | 40 | RCT, Open-label | Aflibercept |
| NCT04992273 COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age | COVID-19 | P2 | Terminated | 7 | Open-label | casirivimab+imdevimab |
| NCT00284141 Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma | Pulmonary Diseases, Neoplasms, Lung | P2 | Completed | 98 | Open-label | Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) |
| NCT01288443 Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy | Hypercholesterolemia | P2 | Completed | 183 | RCT, Double-blind | Alirocumab, Placebo (for alirocumab), Atorvastatin |
| NCT07891182 VGFTe-(HD)-OD-2566: Adjunctive Aflibercept Ahmed Glaucoma Valve (AAA) Study | Glaucoma | P2 | Not Yet Recruiting | 100 | RCT, Open-label | Aflibercept Injection |
| NCT06384820 Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC) | Cutaneous Squamous Cell Carcinoma | P2 | Withdrawn | — | RCT, Open-label | cemiplimab, fianlimab |
| NCT01312961 Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma | Asthma | P2 | Completed | 104 | RCT, Double-blind | Dupilumab, Placebo (for Dupilumab), Fluticasone/Salmeterol combination therapy, Fluticasone monotherapy, Albuterol, Levalbuterol |
| NCT04646005 Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy | Cervical Cancer | P2 | Completed | 113 | Open-label | Cemiplimab, ISA101b |
| NCT01001923 Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis Pain | Abdominal Pain Upper | P2 | Terminated | 15 | RCT, Double-blind | REGN475/SAR164877, Placebo (for REGN475/SAR164877) |
| NCT03175367 Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia | Hypercholesterolemia | P2 | Completed | 272 | RCT, Double-blind | Evinacumab, Matching placebo |
| NCT02418754 Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD) | Neovascular Age-Related Macular Degeneration | P2 | Terminated | 505 | RCT, Double-blind | REGN2176-3, Intravitreal Aflibercept Injection (IAI) |
| NCT01812707 Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in Japan | Hypercholesterolemia | P2 | Completed | 100 | RCT, Double-blind | Alirocumab, Placebo (for alirocumab), Atorvastatin |
| NCT01118728 Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis | Ankylosing Spondylitis | P2 | Terminated | 223 | Open-label | Sarilumab |
| NCT03736967 Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis | Atopic Dermatitis | P2 | Terminated | 206 | RCT, Double-blind | REGN3500, Dupilumab, REGN3500 + Dupilumab Combo, Placebo |
| NCT04126317 Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration | Neovascular (Wet) Age-Related Macular Degeneration | P2 | Completed | 106 | RCT, Single-blind | aflibercept, High-dose aflibercept |
| NCT01882868 A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan | Colorectal Cancer Metastatic | P2 | Completed | 62 | Open-label | Aflibercept, Levofolinate, Irinotecan, 5-FU |
| NCT06833190 REGN5381 in Adult Participants With Uncontrolled Hypertension | Uncontrolled Hypertension | P2 | Terminated | 34 | RCT, Double-blind | REGN5381, Placebo |
| NCT04311606 Anti-VEGF Therapy for Acute Thyroid Eye Disease | Thyroid Eye Disease | P2 | Terminated | 8 | RCT, Double-blind | Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept, Sub-tenon injection of hyaluronidase (HA) followed by a sub-tenon injection of aflibercept, Sub-tenon injection of hyaluronidase (HA) alone |
| NCT02210780 Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD) | Atopic Dermatitis | P2 | Completed | 194 | RCT, Double-blind | Dupilumab, Placebo |
| NCT00789477 DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact | Diabetic Macular Edema | P2 | Completed | 221 | RCT, Double-blind | Intravitreal Aflibercept Injection |
| NCT01724554 Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion | Central Retinal Vein Occlusion, Proliferative Diabetic Retinopathy | P1P2 | Completed | 24 | RCT, Open-label | Intravitreal Aflibercept Injection |
| NCT07620548 Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas | Glioblastoma, Glioblastoma, IDH-wildtype | P2 | Not Yet Recruiting | 99 | RCT, Open-label | Cemiplimab, Chemotherapy |
| NCT06691113 A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps | Chronic Rhinosinusitis Without Nasal Polyps | P2 | Completed | 66 | RCT, Double-blind | Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS) |
| NCT00320788 Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD) | Macular Degeneration | P2 | Completed | 159 | RCT, Double-blind | aflibercept injection (VEGF Trap-Eye, BAY86-5321), aflibercept injection (VEGF Trap-Eye, BAY86-5321), aflibercept injection (VEGF Trap-Eye, BAY86-5321), aflibercept injection (VEGF Trap-Eye, BAY86-5321), aflibercept injection (VEGF Trap-Eye, BAY86-5321) |
| NCT06373146 A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity | Obesity | P2 | Completed | 392 | RCT, Double-blind | Tirzepatide, Mibavademab, Tirzepatide-Placebo, Mibavademab-Placebo |
| NCT01710332 The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy | Central Serous Chorioretinopathy | P2 | Completed | 12 | RCT, Open-label | Intravitreal Aflibercept Injection |
| NCT06052852 Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies | Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma | P1 | Terminated | 17 | Open-label | BDC-3042, Cemiplimab |
| NCT04826393 ASP8374 + Cemiplimab in Recurrent Glioma | Glioblastoma, Recurrent Glioblastoma | P1 | Completed | 14 | RCT, Open-label | ASP8374, cemiplimab |
| NCT00082823 Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma | Cancer | P1 | Completed | 25 | Open-label | ziv-aflibercept |
| NCT03396861 Treatment of Macular Edema After Cataract Surgery with Subconjunctival Aflibercept | Irvine-Gass Syndrome | P1 | Terminated | 1 | Open-label | Aflibercept |
| NCT02107872 Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500 | Metabolic Disorders | P1 | Completed | 55 | RCT, Double-blind | REGN1500, placebo |
| NCT03438318 Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer | P1 | Completed | 29 | Open-label | CMP-001, Atezolizumab |
| NCT06137482 A Study to See How Safe and Tolerable Different Doses of REGN13335 Are When Administered Intravenously (IV) or Subcutaneously (SC) to Healthy Adult Participants | Healthy Volunteers | P1 | Completed | 56 | RCT, Double-blind | REGN13335, Matching Placebo |
| NCT02943239 Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men | Healthy Volunteers | P1 | Completed | 82 | RCT, Double-blind | REGN1033, REGN2477 |
| NCT02061865 Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD | Neovascular Wet Age-related Macular Degeneration (AMD) | P1 | Completed | 12 | Open-label | REGN2176-3 |
| NCT00545246 A Phase I Study of Intravenous Aflibercept in Combination With Docetaxel in Japanese Cancer Patients | Neoplasms | P1 | Completed | 12 | Open-label | aflibercept (AVE0005), docetaxel |
| NCT02383212 Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies | Advanced Cancer, Advanced Malignancies | P1 | Completed | 398 | Open-label | Cemiplimab, Cyclophosphamide, Docetaxel, Carboplatin, GM-CSF, Paclitaxel, Pemetrexed |
| NCT01959971 Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol | Hypercholesterolemia | P1 | Completed | 20 | Single-blind | alirocumab, Placebo |
| NCT02744287 Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors | Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer | P1 | Terminated | 52 | Open-label | BPX-601, Rimiducid |
| NCT00871559 A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies | Advanced Solid Malignancies | P1 | Completed | 83 | Open-label | REGN421(SAR153192) |
| NCT06970405 Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal Women | Obesity | P1 | Withdrawn | — | RCT, Double-blind | Garetosmab, Matching Placebo |
| NCT00383370 Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD | Neovascular Age Related Macular Degeneration | P1 | Completed | 20 | RCT, Double-blind | VEGF Trap, VEGF Trap |
| NCT03746704 Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Adult Participants With Advanced PD-L1 Positive Malignancies | Advanced PD-L1 Positive Malignancies | P1 | Terminated | 2 | Open-label | 89Zr˗DFO˗REGN3504 |
| NCT01723735 Effect of Alirocumab (SAR236553/REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects | Hypercholesterolemia | P1 | Completed | 79 | RCT, Open-label | Alirocumab, Ezetimibe, Ezetimibe Placebo, Fenofibrate |
| NCT03491904 To Assess the Patients' Ability to Self-Administer Fasinumab | Osteoarthritis, Knee, Osteoarthritis, Hip | P1 | Completed | 100 | RCT, Open-label | Fasinumab AI, Fasinumab PFS |
| NCT05157997 Transplantation of Deceased Donors With COVID-19 Into COVID-19 Negative Recipients Utilizing Casirivimab and Imdevimab Antibody Cocktail | COVID-19, Organ Transplant | P1 | Withdrawn | — | Open-label | Casirivimab and Imdevimab Antibody Cocktail |
| NCT03530514 A Study to Examine the Safety, Tolerability and Biological Effects of REGN4461 in Healthy Volunteers | Healthy Volunteers | P1 | Completed | 113 | RCT, Double-blind | REGN4461, Placebo |
| NCT06444178 Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants | Healthy Volunteers | P1 | Completed | 224 | RCT, Open-label | Aspirin, REGN9933, REGN7508, Rivaroxaban |
| NCT02520245 Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study | Advanced Malignancies | P1 | Withdrawn | — | Open-label | REGN2810 |
| NCT04465487 Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies | Squamous Cell Carcinoma of Head and Neck | P1 | Terminated | 38 | Open-label | REGN6569, Cemiplimab |
| NCT01922661 Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Subjects | Allergy | P1 | Completed | 24 | RCT, Double-blind | REGN1908-1909 |
| NCT02290951 Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies | Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | P1 | Completed | 200 | Open-label | Odronextamab multiple dose levels, Odronextamab multiple dose levels |
| NCT05291546 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9035 in Healthy Adult Volunteers and Mildly Hypertensive Participants | Healthy Volunteers | P1 | Completed | 93 | RCT, Double-blind | REGN9035, REGN5381 |
| NCT03112577 Study of REGN3500 and Dupilumab in Patients With Asthma | Asthma, Allergic | P1 | Completed | 32 | RCT, Double-blind | REGN3500, Dupilumab, Placebo, Fluticasone propionate |
| NCT02204683 Pharmacokinetic Study of Intravitreal Aflibercept Injection in Eyes With Wet Age-related Macular Degeneration | Neovascular Macular Degeneration | P1 | Completed | 5 | Open-label | Aflibercept |
| NCT05976386 Single Dose Comparability Study of New and Current Dupilumab Drug Products Subcutaneously Administered in Healthy Adults | Healthy Volunteers | P1 | Completed | 182 | RCT, Open-label | Dupilumab (SAR231893) |
| NCT01785329 Pharmacokinetic of Alirocumab SAR236553 (REGN727) Administered Subcutaneously at 3 Different Injection Sites in Healthy Subjects | Hypercholesterolemia | P1 | Completed | 60 | RCT, Open-label | alirocumab SAR236553 (REGN727) |
| NCT05976373 A Study to Investigate the Pharmacokinetics (PK), Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants. | Healthy Volunteers | P1 | Completed | 38 | RCT, Open-label | Dupilumab (SAR231893) |
| NCT01910220 Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786) | Healthy Volunteers | P1 | Completed | 125 | RCT, Double-blind | REGN1033 (SAR391786) |
| NCT02828397 Study of the Blood Concentrations of Two Formulations of REGN2222 in Healthy Subjects | Healthy Volunteers | P1 | Completed | 28 | RCT, Open-label | REGN2222 |
| NCT05970718 A Trial to Learn if Different Doses of REGN7544 Are Safe in Healthy Adult Participants | Healthy Volunteers | P1 | Completed | 80 | RCT, Double-blind | REGN7544, Matching Placebo |
| NCT02999711 Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate Asthma | Asthma, Moderate Asthma | P1 | Completed | 23 | RCT, Double-blind | REGN3500, Placebo |
| NCT00921661 Study of Intravenous Aflibercept in Combination With FOLFIRI in Japanese Patients With Metastatic Colorectal Cancer | Colorectal Neoplasms, Neoplasm Metastasis | P1 | Completed | 16 | Open-label | AVE0005 (aflibercept) |
| NCT01259323 Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis | Dermatitis | P1 | Completed | 30 | RCT, Double-blind | REGN668, REGN668, REGN668 |
| NCT03005782 Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers | Malignancies | P1 | Completed | 333 | Open-label | REGN3767, cemiplimab |
| NCT01537653 Safety, Tolerability and Pharmacokinetics of SAR231893 (REGN668) in Healthy Japanese Adult Male Subjects | Healthy | P1 | Completed | 32 | RCT, Double-blind | SAR231893 (REGN668), placebo |
| NCT05505448 A Trial to Learn if a COVID-19 Therapeutic is Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants | Healthy | P1 | Completed | 48 | RCT, Double-blind | REGN14284, Matching Placebo |
| NCT04982224 Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer | Advanced NSCLC | P1 | Terminated | 30 | Open-label | REGN5093-M114, Cemiplimab |
| NCT01026519 A Safety and Tolerability Study of REGN88(SAR153191) in Subjects With Rheumatoid Arthritis | Rheumatoid Arthritis | P1 | Completed | 32 | RCT, Double-blind | REGN88 |
| NCT01443650 Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects | Hypercholesterolemia | P1 | Completed | 36 | RCT, Double-blind | alirocumab SAR236553 (REGN727) |
| NCT07876505 Healthy Adult Participants Trial Comparing Different Cenvacibart Presentations | Healthy Volunteers | P1 | Not Yet Recruiting | 80 | RCT, Open-label | Cenvacibart |
| NCT04940364 A Study to Examine the Safety, Tolerability and Biological Effects of Single Doses of Subcutaneously and Intravenously Administered Pozelimab as Monotherapy and in Combination With Single Doses of Subcutaneously Administered Cemdisiran in Adult Japanese Healthy Volunteers | Healthy | P1 | Completed | 30 | Open-label | Pozelimab, Cemdisiran |
| NCT03146416 Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers | Healthy Volunteers | P1 | Completed | 96 | RCT, Double-blind | Evinacumab, Placebo |
| NCT02284425 Study of REGN1193 in Patients With Type 2 Diabetes Mellitus | Diabetes Mellitus, Type 2 | P1 | Terminated | 72 | RCT, Double-blind | REGN1193, Placebo |
| NCT00644124 Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma | Lymphoma, Non-Hodgkin | P1 | Completed | 25 | Open-label | aflibercept |
| NCT01161082 Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin | Hypercholesterolemia | P1 | Completed | 72 | RCT, Double-blind | REGN727(SAR236553) |
| NCT03002376 An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1) | Melanoma | P1 | Completed | 47 | Open-label | REGN2810 |
| NCT02516618 Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian Subjects | Healthy Volunteers | P1 | Completed | 72 | RCT, Double-blind | Fasinumab, Placebo |
| NCT06024408 A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor | Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH) | P1 | Completed | 9 | RCT, Double-blind | ALN-PNP, Placebo |
| NCT02958436 A Study of Intravenously or Subcutaneously Administered REGN3500 in Healthy Adult Subjects | Healthy Volunteers | P1 | Completed | 40 | RCT, Double-blind | REGN3500, Placebo |
| NCT06669234 Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults | Healthy Volunteer | P1 | Completed | 56 | RCT, Double-blind | ALN-F1202, Matching Placebo |
| NCT00083213 Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma | Cancer | P1 | Completed | 25 | Open-label | ziv-aflibercept |
| NCT03115996 Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN3918 in Healthy Volunteers | Healthy Volunteers | P1 | Completed | 56 | RCT, Double-blind | REGN3918, Placebo |
| NCT05181683 COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers | Healthy, Chronic Stable Illness | P1 | Completed | 45 | RCT, Open-label | Casirivimab+Imdevimab |
| NCT03645746 Safety, Tolerability, and Pharmacokinetics of REGN5069 in Healthy Volunteers | Healthy Volunteer | P1 | Completed | 56 | RCT, Double-blind | REGN5069, Placebo |
| NCT02127801 Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants | Allergy | P1 | Completed | 74 | RCT, Double-blind | REGN1908-1909, placebo |
| NCT01579760 Intravitreal Aflibercept Injection for Radiation Retinopathy | Radiation Retinopathy, Macular Edema | P1 | Completed | 9 | RCT, Single-blind | Aflibercept every 2 months, Aflibercept monthly |
| NCT01209793 Safety and Tolerability Study of REGN846 (SAR302352) in Healthy Volunteers | Healthy | P1 | Completed | 40 | RCT, Double-blind | REGN846 |
| NCT04616105 Study of the Safety, Tolerability, and Pharmacokinetics of REGN6490 in Healthy Japanese Adult Volunteers | Healthy Volunteer | P1 | Terminated | 19 | RCT, Double-blind | REGN6490, Placebo |
| NCT00036946 VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma | Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific | P1 | Completed | — | — | ziv-aflibercept |
| NCT04506645 Study to Assess the Safety, Tolerability, and Pharmacokinetics of REGN5381 (an NPR1 Agonist) in Adult Humans | Healthy | P1 | Completed | 90 | RCT, Double-blind | REGN5381 |
| NCT02870400 A Study to Examine the Safety and Tolerability of Single Ascending Doses of REGN2477 | Healthy Volunteers | P1 | Completed | 41 | RCT, Double-blind | REGN2477, Placebo |
| NCT05064085 Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer | Hormone Receptor-positive Breast Cancer | P1 | Completed | 13 | Open-label | Cemiplimab, Capecitabine |
| NCT07861152 Thyroid-Stimulating Hormone Receptor (TSHR) Blockade With REGN24493 in Adult Participants With Graves' Disease (GD) | Graves' Disease | P1 | Not Yet Recruiting | 45 | RCT, Double-blind | REGN24493, Placebo |
| NCT01688960 Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies | Solid Tumors | P1 | Completed | 48 | Open-label | nesvacumab (REGN910/ SAR307746), nesvacumab (REGN910/ SAR307746), nesvacumab (REGN910/ SAR307746), aflibercept (ziv-aflibercept), aflibercept (ziv-aflibercept) |
| NCT01537640 Comparison of the Pharmacokinetics and Safety of Two SAR231893 (REGN668) Drug Products in Healthy Subjects | Healthy | P1 | Completed | 30 | RCT, Double-blind | SAR231893 (REGN668) DP1, SAR231893 (REGN668) DP2 |
| NCT05169489 A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) | Diffuse Large B Cell Lymphoma (DLBCL) | P1 | Terminated | 15 | Open-label | bbT369 |
| NCT03969849 Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Participants | Healthy Volunteers, Birch Pollen Allergy | P1 | Completed | 96 | RCT, Double-blind | REGN5713-5714-5715, Matching placebo |
| NCT01933763 An Ascending Single-Dose Study of the Safety, Tolerability and Bioeffect of REGN1193 | Healthy Volunteers | P1 | Completed | 56 | RCT, Double-blind | REGN1193 |
| NCT00856310 A Single-Dose Study of the Safety and Tolerability of REGN475(SAR164877) in Healthy Subjects | Healthy | P1 | Completed | 56 | RCT, Double-blind | REGN475 (SAR164877) |
| NCT02121080 Study of the Safety and Tolerability of REGN2222(SAR438584) in Healthy Adult Volunteers | Healthy Volunteers | P1 | Completed | 132 | RCT, Double-blind | REGN2222(SAR438584), placebo |
| NCT04409080 REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy | Severe Aplastic Anemia (SAA) | P1 | Terminated | 17 | Open-label | REGN7257 |
| NCT01850680 Single Ascending Dose Study of Safety and Tolerability of Sarilumab and Methotrexate in Japanese Patients With Rheumatoid Arthritis | Rheumatoid Arthritis | P1 | Completed | 61 | RCT, Double-blind | sarilumab SAR153191 (REGN88), placebo, methotrexate, folic acid |
| NCT01328522 Comparison of the Safety and Pharmacokinetics of Two SAR153191 (REGN88) Drug Products in Rheumatoid Arthritis Patients | Rheumatoid Arthritis | P1 | Completed | 32 | RCT, Single-blind | SAR153191 (REGN88) |
| NCT01448317 Ascending Dose Study of the Safety and Tolerability of Alirocumab (SAR236553/REGN727) in Japanese Healthy Volunteers | Hypercholesterolemia | P1 | Completed | 32 | RCT, Double-blind | Alirocumab (Solution), Alirocumab (Lyophilized formulation), Placebo (Solution), Placebo (Lyophilized formulation) |
| NCT05293678 Safety and Tolerability of Regeneron Anti-SARS-CoV-2 Monoclonal Antibody/Ies in Adult Healthy Volunteers as Related to COVID-19 | Healthy | P1 | Completed | 104 | RCT, Double-blind | REGN15160 (IV), Matching Placebo (IV), REGN15160 (SC), Matching Placebo (SC) |
| NCT01868360 Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea | Corneal Neovascularization | P1 | Terminated | 2 | RCT, Open-label | Subconjunctival aflibercept |
| NCT05054348 First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors | Solid Tumor, Adult | P1 | Completed | 91 | Open-label | IO-108, IO-108 + pembrolizumab combination therapy, IO-108 + cemiplimab combination therapy |
| NCT01197391 Ascending Dose Study of the Safety and Tolerability of REGN728 in Healthy Volunteers | Healthy | P1 | Completed | 48 | RCT, Double-blind | REGN728 |
| NCT01026597 Ascending Dose Study of the Safety and Tolerability of REGN727(SAR236553) in Healthy Volunteers | Healthy | P1 | Completed | 40 | RCT, Double-blind | REGN727, Placebo |
| NCT04616079 Ascending Dose Study of the Safety and Tolerability of REGN6490 in Healthy Volunteers | Healthy Volunteer | P1 | Terminated | 57 | RCT, Double-blind | REGN6490, Placebo |
| NCT02647086 Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD) | Atopic Dermatitis | P1 | Completed | 14 | Open-label | Dupilumab, Midazolam, Omeprazole, Warfarin, Caffeine, Metoprolol |
| NCT02017639 Sarilumab Effect on the Pharmacokinetics of Simvastatin | Rheumatoid Arthritis | P1 | Completed | 19 | Open-label | sarilumab SAR153191 (REGN88), simvastatin |
| NCT05013723 Impact of Monoclonal Antibody Treatment on Post-Acute COVID-19 Syndrome | Post-acute COVID-19 (PACS), or "long COVID" Syndrome | Completed | 260 | — | — | |
| NCT03507374 PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis | Stroke, Intracranial Atherosclerosis | Early P1 | Terminated | 20 | RCT, Double-blind | Alirocumab, Placebo |
| NCT05203380 Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis | Moderate-to-severe Atopic Dermatitis | Completed | 45 | — | dupilumab | |
| NCT01773954 Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular Degeneration | Age-Related Macular Degeneration, Macular Degeneration | N/A | Completed | 40 | Open-label | Intravitreal Aflibercept Injection |
| NCT06064656 A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP) | Fibrodysplasia Ossificans Progressiva (FOP) | Completed | 131 | — | — | |
| NCT05991323 Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study | Prurigo Nodularis | Completed | 110 | — | Dupilumab | |
| NCT05423327 Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH) | Non-alcoholic Steatohepatitis (NASH) | N/A | Terminated | 5,311 | Open-label | — |
| NCT03576690 R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease | Ebola Virus Disease | AVAILABLE | — | — | REGN3470-3471-3479 | |
| NCT01783925 Eylea Post Marketing Surveillance(PMS) | Macular Degeneration | Completed | 3,206 | — | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | |
| NCT02811692 Study for Collection of Aflibercept Data in Routine Practice | Eye Diseases | Completed | 425 | — | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | |
| NCT04550962 Description of Characteristics, Such as Age, Previous and Concurrent Treatments, Associated Diseases, of Patients With Asthma Treated With Dupilumab (DUPIXENT) | Asthma | Completed | 376 | — | Dupilumab SAR231893 | |
| NCT03278262 The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical Setting | Wet Macular Degeneration | Completed | 2,312 | — | Aflibercept (Eylea, BAY86-5321) | |
| NCT07316114 A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria | Chronic Spontaneous Urticaria | Terminated | 1 | — | Dupilumab | |
| NCT05906706 Compassionate Use of Dupilumab for Adult Patients With Bullous Pemphigoid | Bullous Pemphigoid | APPROVED_FOR_MARKETING | — | — | dupilumab | |
| NCT03836105 CemiplimAb Survivorship Epidemiology | Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma | Completed | 287 | — | cemiplimab | |
| NCT06019481 A Natural History Study in Pediatric Participants With Hearing Loss Due to OTOF, GJB2, or GJB2/GJB6 Mutations | Congenital Hearing Loss Secondary to Biallelic Mutations in the Otoferlin Gene (OTOF), Biallelic Mutations in the Gap Junction Beta 2 (GJB2) Gene | Withdrawn | — | — | — | |
| NCT01771081 Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy | Ophthalmology, Macular Edema | Completed | 911 | — | Ranibizumab (or other DME treatment) | |
| NCT01418781 CLinical Prediction Rule Score in Veterans | Gout | Withdrawn | — | — | — | |
| NCT01714115 Use of Eylea for the Treatment of an Optic Nerve Hemangioma | Retinal Hemangioma | NO_LONGER_AVAILABLE | — | — | Aflibercept | |
| NCT04617535 Compassionate Use of REGN-COV2 for the Treatment of COVID-19 | COVID-19 | NO_LONGER_AVAILABLE | — | — | REGN10933+REGN10987 combination therapy | |
| NCT04722068 Regeneron 1331 Kinetics Sub-Study HoFH | Hypercholesterolemia, Familial | N/A | Completed | 4 | Open-label | — |
| NCT05232110 Compassionate Use of Pozelimab | CD55-deficient Protein-losing Enteropathy | APPROVED_FOR_MARKETING | — | — | Pozelimab | |
| NCT05338879 Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed or Refractory Follicular Lymphoma | Relapsed/Refractory Follicular Lymphoma | Completed | 247 | — | — | |
| NCT06028594 Compassionate Use of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria | Paroxysmal Nocturnal Hemoglobinuria | NO_LONGER_AVAILABLE | — | — | Pozelimab, Cemdisiran | |
| NCT05546957 Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants | Healthy Volunteer | N/A | Completed | 60 | RCT, Open-label | Aspirin, rivaroxaban low dose, rivaroxaban high dose |
| NCT06631677 Expanded Access of Dupilumab in Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy Previously Treated With Linvoseltamab | Food Allergy | AVAILABLE | — | — | Dupilumab | |
| NCT06500598 Compassionate Use of Evinacumab | Pediatric Homozygous Familial Hypercholesterolemia (HoFH), Severe Hypertriglyceridemia (HTG) | APPROVED_FOR_MARKETING | — | — | Evinacumab | |
| NCT04173442 Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy | Atopic Dermatitis (AD), Asthma | Completed | 581 | — | dupilumab | |
| NCT05870215 Phenotyping Responses to Systemic Corticosteroids in the Management of Asthma Attacks | Asthma | Completed | 78 | — | — | |
| NCT05619367 A Compassionate Use (CU) Program of Odronextamab | Relapsed or Refractory (R/R) Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL) | AVAILABLE | — | — | Odronextamab | |
| NCT07105228 Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study | Retinal Vasculitis | Completed | 290,000 | — | aflibercept 2mg | |
| NCT02040220 Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Eylea for Central Retinal Vein Occlusion (CRVO) | Retinal Vein Occlusion | Completed | 385 | — | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | |
| NCT06769412 A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US) | Retinal Vasculitis | Completed | 550,000 | — | aflibercept 2 mg | |
| NCT02321241 Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD | Wet Macular Degeneration | Completed | 236 | — | Aflibercept (EYLEA, BAY-86-5321) | |
| NCT02645747 Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion | Retinal Vein Occlusion | Completed | 126 | — | Aflibercept (Eylea, BAY86-5321) | |
| NCT03378219 An Observational Study on Sarilumab-exposed Pregnancies | Rheumatoid Arthritis -Exposure During Pregnancy | Completed | 113 | — | Sarilumab SAR153191 (REGN88) | |
| NCT05673967 Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma | Relapsed and Refractory Multiple Myeloma (RRMM) | Completed | 62 | — | — | |
| NCT05302297 Comparative Efficacy of Cemiplimab to Historical Standard of Care in France | Cancer/Squamous Cell Carcinoma of Skin | Completed | 305 | — | Cemiplimab | |
| NCT05164250 Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM) | Multiple Myeloma | APPROVED_FOR_MARKETING | — | — | REGN5458 | |
| NCT03382587 Observational Study to Assess Intravitreal Aflibercept Injections Used in a "Treat and Extend" Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients | Wet Age-related Macular Degeneration | Completed | 163 | — | Aflibercept (Eylea, BAY86-5321) | |
| NCT03228693 Gene Expression and Biomarker Profiling of Keloid Skin | Keloid, Keloid of Ear Lobe | N/A | Completed | 48 | Open-label | — |
| NCT06132191 Expanded Access Use of Cemiplimab in Patients With Solid Tumors | Non-Small Cell Lung Cancer (NSCLC), Basal Cell Carcinoma (BCC) | APPROVED_FOR_MARKETING | — | — | Cemiplimab | |
| NCT02585401 Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada | Age-related Macular Degeneration (AMD), Central Retinal Vein Occlusion (CRVO) | Completed | 99 | — | Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321) | |
| NCT04287608 Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis | Conjunctivitis, Atopic Dermatitis | Completed | 50 | — | dupilumab | |
| NCT04287621 Registry of Asthma Patients Initiating DUPIXENT® | Asthma | Completed | 718 | — | DUPIXENT® | |
| NCT03411941 Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD) | Macular Degeneration | Completed | 116 | — | Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321) | |
| NCT03051347 Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments | Atopic Dermatitis, Ichthyosis | N/A | Completed | 943 | Open-label | — |
| NCT01756261 EYLEA [AMD-QOL(Age-Related Macular Degeneration-Quality of Life)] Post-marketing Surveillance in Japan | Macular Degeneration | Completed | 757 | — | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | |
| NCT02541084 Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan | Wet Macular Degeneration | Completed | 72 | — | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | |
| NCT04614571 T Cell Receptor (TCR) Sequencing and Transcriptional Profiling in Adult Celiac Disease Patients Undergoing Gluten Challenge | Celiac Disease | N/A | Completed | 24 | Open-label | — |